Urological cancer research

Based at the Faculty of Health and Plymouth Hospitals NHS Trust, but working with clinical colleagues and patients across the UK and internationally, our major areas of interest are:

  • management of urological cancers
  • early drug development and translational medicine
  • clinical trials – set-up and running of large numbers of clinical trials, from early phase to late phase studies
  • providing early access to novel drugs for patients.

Examples of key studies include: 

Organ preservation in bladder cancer

Our research in this area moved all the way from

This study has now changed the standard of care for patients with muscle invasive bladder cancer opting for organ preservation treatment.

Split dose cisplatin in bladder cancer

Our work has extended the spectrum of patients receiving cisplatin based chemotherapy (Hussain et al BJC 2004).

Professor Syed Hussain

Professor of Oncology, Faculty of Medicine and Dentistry
Consultant in Medical Oncology, Plymouth Hospitals NHS Trust


  • Andronis L, Hussain SA, et al.  2017 'Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)' BJU International119, (4), 522-529. Read article  
  • Hussain S, Palmer D, Syn W-K, Sacco J, Greensmith R, Elmetwali T, Aachi V, Lloyd B, Jithesh P & Arrand J 2017 'Gene expression profiling in bladder cancer identifies potential therapeutic targets' International Journal of Oncology, 50, (4), 1147-1159. Read article
  • Necchi A, Hussain S, et al. 2017 'Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study' European Urology Focus , Read article.
  • Choudhury A, West CM, Porta N, Hall E, Denley H, Hendron C, Lewis R, Hussain SA, Huddart R & James N 2017 'The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)' British Journal of Cancer 116, (5) 649-657 , Read article.
  • Powles T, Hussain S, et al.  2016 'A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer' European Urology 69, (3) 450-456 , Read article.